Validation of a questionnaire for cognitive decline in German
German Validation Study of the Subjective Cognitive Decline Questionnaire (SCD-Q) and Its Potential Use in Large Cohorts
This study is testing a new questionnaire in German to see if it can help people undergoing dementia tests understand their own memory changes and how those changes relate to Alzheimer's disease.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 300 (estimated) |
| Ages | 50 Years and up |
| Sex | All |
| Sponsor | Ludwig-Maximilians - University of Munich Academic / other |
| Locations | 1 site (München, Bavaria) |
| Trial ID | NCT06711952 on ClinicalTrials.gov |
What this trial studies
This study aims to validate the Subjective Cognitive Decline Questionnaire (SCD-Q) in the German language for patients undergoing dementia diagnostics. The SCD-Q is a screening tool that assesses self-perceived cognitive decline and includes both self-reported and informant-rated versions. The study will also explore the relationship between the SCD-Q results and various biomarkers associated with Alzheimer's disease, as well as cognitive tests. Follow-up visits will be conducted to gather comprehensive data on cognitive changes over time.
Who should consider this trial
Good fit: Ideal candidates are individuals attending medical appointments for dementia diagnostics who can provide informed consent.
Not a fit: Patients with advanced-stage dementia or those who are illiterate may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide a validated tool for early detection of cognitive decline in German-speaking populations.
How similar studies have performed: Other studies have successfully validated similar cognitive assessment tools, but this specific validation in German is novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Medical appointment for dementia diagnostics at the Alzheimer Therapie- und Forschungszentrum * Provision of signed, written and dated informed consent * Capacity to give informed consent Exclusion Criteria: * dementia in a very advance stage * Illiteracy
Where this trial is running
München, Bavaria
- Klinik und Poliklinik für Psychiatrie und Psychotherapie des LMU Klinikums — München, Bavaria, Germany (Recruiting)
Study contacts
- Principal investigator: Robert Perneczky, Prof. Dr. — Klinik und Poliklinik für Psychiatrie und Psychotherapie des LMU Klinikums
- Study coordinator: Carolin Kurz, Dr.
- Email: Psy.Alzheimerzentrum@med.uni-muenchen.de
- Phone: +4989440055863
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.